Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-26a
- Development stage
- Preclinical
- Lead developer
- Cleveland Clinic
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Intratumoral
01
Overview
miR-26a is a microRNA molecule being investigated as a therapeutic agent for multiple myeloma and other cancers. It acts as a tumor suppressor by post-transcriptionally regulating gene expression. Specifically, miR-26a binds to the 3' untranslated region (UTR) of the CD38 mRNA, inhibiting its translation into protein. In multiple myeloma, downregulation of CD38 by miR-26a leads to reduced cell proliferation, increased apoptosis, and may sensitize cells to treatments such as daratumumab, bortezomib, and melphalan. Preclinical research has explored various delivery systems, including single-wall carbon nanotubes, to transport miR-26a mimics to tumor sites in vivo.
- Other names
- microRNA-26amicroRNA26amicroRNA 26ahsa-miR-26ahsa-miR26ahsa-miR 26a
02
Targets
CDK6 (Cyclin-dependent kinase 6)EZH2 (Histone-lysine N-methyltransferase EZH2)GSK3 (Glycogen synthase kinase 3 beta)HMGA1 (High mobility group AT-hook 1)MALT1 (Mucosa-associated lymphoid tissue lymphoma translocation protein 1)PTEN (Phosphatase and tensin homolog deleted on chromosome ten)Mothers against decapentapentaplegic homolog 1 mRNACD38 (Cluster of Differentiation 38)
Beyond the preview
Go deeper on miR-26a.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-26a.